Clinical Trials
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2101
Biomarker Stratified CaboZantinib and NivOlumab (BiCaZO) - A phase II study of combining cabozantinib and nivolumab in patients with advanced solid tumors stratified by tumor biomarkers
Status Notes
Activation: Effective October 14, 2022 at 12:00 PM Pacific Time
Research Committee(s)
iMATCH
Head and Neck Cancer
Melanoma
Early Therapeutics & Rare Cancers
Activated
10-14-2022
ClinicalTrials.gov Registry Number
NCT 05136196
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09-19-2022
ClinicalTrials.gov Registry Number
NCT05411081
Open
Phase
Accrual
1%
SWOG Clinical Trial Number
S2108CD
A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (eGTB) Intervention to Usual Practice to Increase Evidence-Based Genome Informed Therapy
Status Notes
This study is open for patient accrual effective August 22, 2022.
Research Committee(s)
Cancer Care Delivery
Activated
08-22-2022
ClinicalTrials.gov Registry Number
NCT # 05455606
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S1900F
A Randomized Phase II Study of Carboplatin and Pemetrexed with or without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)
Status Notes
Activated 7/25/2022
Research Committee(s)
LungMAP
Activated
07-25-2022
ClinicalTrials.gov Registry Number
05364645
Open
Phase
Accrual
8%
SWOG Clinical Trial Number
S2107
Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Status Notes
Activation Date: 06/06/2022
Research Committee(s)
Gastrointestinal Cancer
Activated
06-06-2022
ClinicalTrials.gov Registry Number
NCT05308446
Open
Phase
Accrual
12%
SWOG Clinical Trial Number
S1800D
A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
Status Notes
S1800D will open to accrual February 15, 2022, effective 12:00 pm PST. This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
02-15-2022